Tumour-agnostic kinase inhibitors

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Protein kinases are vital in cancer development and are frequent targets for therapy.
• The development of kinase inhibitors has enabled a shift towards biomarker-based, tumor-agnostic treatment strategies.
• Several kinase inhibitors have received regulatory approval for specific genetic alterations, irrespective of tumor origin.

Purpose of the Study:

• To review the precision medicine paradigm in developing tumor-agnostic kinase inhibitors.
• To highlight the successes and challenges in targeting kinase pathway aberrations.
• To discuss the implications for clinical trials and regulatory approvals.

Main Methods:

• Review of existing literature on tumor-agnostic kinase inhibitors.
• Analysis of regulatory approvals and clinical trial designs.
• Focus on small-molecule inhibitors targeting kinase pathway aberrations.

Main Results:

• Tumor-agnostic drug development has led to transformative approvals for kinase inhibitors.
• Current approvals are often partial, excluding either solid or hematological cancers.
• Clinical trials for these agents require extensive genomic sequencing to identify eligible patients.

Conclusions:

• The precision medicine model has successfully advanced tumor-agnostic drug development for kinase inhibitors.
• Significant challenges remain in achieving comprehensive approvals and efficient clinical trial designs.
• Further research is needed to overcome hurdles in developing truly universal tumor-agnostic kinase inhibitors.